Menin Inhibitors: A New Class of Anti-Leukemic Agents
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 19th Year in a Row
Innovative Roswell Park Radiation Therapy Protocol in Lung Cancer to Be Highlighted at ASTRO Annual Meeting
Cracking the Code
New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis
Dana-Farber Treats First Patient with Approved Gene Therapy for Beta Thalassemia
Clinical Trials and Research for Mantle Cell Lymphoma
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
Showing 16 - 30 of 1049 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...70 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
